COVID-19 treatment changes infant’s eye color


The 6-month-old boy’s dark brown eyes turned deep blue after he was treated for COVID with favipiravir.

©zotyaba  /

The 6-month-old boy’s dark brown eyes turned deep blue after he was treated for COVID with favipiravir. (Image Credit: ©zotyaba -

An online report in Live Science described a rare side effect of favipiravir, an antiviral drug used to treat COVID-19.1 The 6-month-old boy’s dark brown eyes turned deep blue after he was treated for COVID with favipiravir.

The baby, who lives in Thailand, had been treated with favipiravir for 3 days and the treatment helped improve the COVID symptoms. However, the physician ordered the treatment stopped because of the change in color of the eyes, which returned to their original brown color 5 days after favipiravir was stopped.

Favipiravir was approved for use in China, in 2020 and then approval followed in India, Japan, and Thailand, to treat mild-to-severe COVID-19. In Thailand, according to the report, favipiravir is the main antiviral given to children infected with SARS-CoV-2.

Diarrhea, decreased numbers of circulating white blood cells and elevated blood uric acid levels are the most common side effects of favipiravir. However, the definitive causes of changes in eye color are only theories.

According to the report, Vik Sharma, MD, a London surgeon not involved in the baby’s case, theorized the color change may have resulted from the release of fluorescent chemicals as the drug breaks down and accumulate in the cornea. A previous study reported that researchers found that favipiravir can also cause fluorescence in human hair and nails.2

In the patient under discussion, examination showed discovered a buildup of blue pigment in both corneas. The treating physicians theorized that this fluorescence "may be due to the drug, its metabolites, or additional tablet components such as titanium dioxide and yellow ferric oxide." The change in the baby’s eyes appeared to be temporary with no long-term effects or visual changes. The physicians reported the case in Frontiers in Pediatrics.3

They commented that the favipiravir tablets fluoresced under ultraviolet light in the laboratory, and the drug's fluorescent components may accumulate in different tissues.

A few other cases of color changes have been reported. In one the surface of a patient’s eye glowed blue, in other cases, patients’ eyes, teeth, and nails fluoresced.

"More work is needed to determine the exact cause [of the eye discoloration] and any long-term effects," Sharma said.

  1. Wong C. Infant's dark-brown eyes suddenly turn indigo blue after COVID-19 antiviral treatment. But why? LiveScience 2023; published online September 4; doi:10.3389/fped.2023.1154814. CC BY 4.0
  2. Kayiran MA, Cebeci F, Erdemir VA, et al. Fluorescence of nails and hair on Wood's lamp examination in Covid pandemic; undefined effect of Favipiravir in humans. Derm Ther. 2021;
  3. Jiravisitkul P, Thonginnetta S, Wongvisavavit R. Case report: Favipiravir-induced bluish corneal discoloration in infant with COVID-19. Front Pediatr. 2023;11;
Related Videos
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
© 2024 MJH Life Sciences

All rights reserved.